glaxosmithkline

What to Watch: July 16, 2012

what to watch, hgsi, gsk, hum, citigroup, humana, glaxosmithkline, human genome sciences, fnno, business, finance, trading, stock market, analysis, news

By FNNO Staff
fnnonline@gmail.com

GSK Extends Offer for Human Genome Again

Published on Fri, 06/29/2012 - 09:45
By FNNO Staff in acquisition, analysis, bid, business, finance, glaxosmithkline, human genome, investing, market, news, stock, trading
market, stock, analysis, trading, business, finance, news, investing, glaxosmithkline, human genome, bid, acquisition

By FNNO Staff
fnnonline@gmail.com

GlaxoSmithKline Extends Offer to Human Genome

Published on Fri, 06/08/2012 - 15:49
By FNNO Staff in analysis, business, company, diabetes, finance, fnno, glaxosmithkline, gsk, human genome, market, news, offer, pharmaceuticals, stock, takeover, trading
business, finance, trading, stock, market, analysis, news, fnno, glaxosmithkline, gsk, human genome, pharmaceuticals, company, offer, takeover, diabetes

By FNNO Staff
fnnonline@gmail.com

What's In The News: April 25, 2012

wall street, wsj, gasoline, crude, reuters, facebook, fb, instagram, microsoft, nyse, msft, human genome sciences, hgsi, glaxosmithkline, gsk, bloomberg, wal-mart, wmt, mexico, united states, business, finance, investing, stock, news, trading, analysis, market

By FNNO Staff
fnnonline@gmail.com

Impax & GlaxoSmithKline Parkinson's Drug Meets Main Goal in Study

Published on Mon, 08/15/2011 - 13:34
By FNNO Staff in General Interest, business, finance, glaxosmithkline, gsk, impax, investing, ipax, news, parkinson's disease, trading, News Update

Patients treated with the drug had significantly less "off time," or waking time when their medication wore off and the motor symptoms of Parkinson's disease returned.

GlaxoSmithKline has a potential upside of 20.6% based on a current price of $41.93 and an average consensus analyst price target of $50.58.

business, finance, glaxosmithkline, gsk, impax, investing, ipax, news, parkinson's disease, trading

Impax Laboratories and GlaxoSmithKline (NYSE:GSK) said that their extended-release experimental drug for Parkinson's disease met its main goal in a late-stage study. The clinical trial measured the effectiveness of the drug, IPX06

By FNNO Staff
fnnonline@gmail.com

GlaxoSmithKline to Cut 130 Jobs

Published on Thu, 07/07/2011 - 13:28
By FNNO Staff in General Interest, GSK, business, finance, glaxosmithkline, investing, job, losses, market, news, stock, trading, News Update

As part of the move, 48 jobs will be lost to the company's Panadol unit in Spain.

The jobs will be cut between now and 2014.

GlaxoSmithKline has a potential upside of 3.9% based on a current price of $43.79 and an average consensus analyst price target of $45.5.

GlaxoSmithKline is currently above its 50-day moving average (MA) of $42.64 and above its 200-day of $40.06.

business, finance, glaxosmithkline, investing, job, losses, market, news, stock, trading

Pharmaceutical company, GlaxoSmithKline (NYSE:GSK) plans to cut 130 jobs in Waterford, Ireland. The company currently employs 700 staff members at the Waterford facility.

By FNNO Staff
fnnonline@gmail.com

What's In The News: May 06, 2011

business, charles, credit suisse, cs, finance, general motors, glaxosmithkline, gm, gsk, investing, news, nyse euronext, opel, pfe, pfizer, schumer, stock

This is what's in the news for Friday, May 6th. the Wall Street Journal reports that Sen. Charles Schumer (D-NY) hasn't publicly taken a position on bids for the New York Stock Exchange (NYX) but behind the scenes he's now favorin

By FNNO Staff
fnnonline@gmail.com

GlaxoSmithKline in Talks to Settle 1,000 Avandia Cases

Glaxo is in settlement talks with attorneys for an estimated 1,000 former Avandia users.

Glaxo shares are down 0.42%, or $0.18, to $43.06.

avandia, business, diabetes, drug, finance, glaxosmithkline, investing, lawsuit, news, patients, settlement, shares, stock

Shares of GlaxoSmithKline (GSK) are down after Bloomberg, citing a lawyer for the patients, reported that the drug maker is set to resolve 1,000 more lawsuits over medicines, including the diabetes drug Avandia.

By FNNO Staff
fnnonline@gmail.com

GlaxoSmithKline Reports Mixed Results, Profit Beats, Revs Miss

Published on Wed, 04/27/2011 - 11:11
By FNNO Staff in General Interest, analysis, earnings, eps, finance, glaxosmithkline, gsk, investing, news, stock, trading, Earnings Reports

Chief Executive Andrew Witty said in a statement, "These first quarter results are in line with the expectation that I set out in February that GSK will make significant progress during 2011 to improve sales performance, enhance c

Shares of GlaxoSmithKline are trading up 1.65% at $42.41.

analysis, earnings, eps, finance, glaxosmithkline, gsk, investing, news, stock, trading

GlaxoSmithKline Plc (NYSE:GSK) reported a Q1 profit of $2.71 billion, beating the consensus estimate for $2.55 billion. Revenues were down 10.5% year-over-year to $10.90 billion, below the consensus estimate for $11.02 billion.

By FNNO Staff
fnnonline@gmail.com

GlaxoSmithKline to Divest Non-Core OTC Products

Published on Thu, 04/14/2011 - 12:42
By FNNO Staff in General Interest, analysis, business, financial, glaxosmithkline, gsk, market, news, pharmaceuticals, stock, trading, News Update

The intention to divest non-core consumer assets was first announced in the company's fourth quarter results Feb. 3, the WSJ reported.

GSK will start communicating with interested parties over the next few weeks, and hopes to divesting the products by late 2011, the report added.

Shares are up 0.62% to $40.75.

analysis, business, financial, glaxosmithkline, gsk, market, news, pharmaceuticals, stock, trading

GlaxoSmithKline (GSK) announced that it has identified non-core OTC brands that it plans to divest to allow its consumer health care business to focus on a smaller portfolio of fast growing products and emerging markets, the Wall

By FNNO Staff
fnnonline@gmail.com

Latest News from FNNO

Shares of YRC Worldwide Have Risen Above...

Shares of YRC Worldwide (NASDAQ:YRCW) traded at a new 52-week high today of $30.49. Th ...

Watch for Continued Gains in Shares of T...

Shares of TRW Automotive (NYSE:TRW) traded at a new 52-week high today of $66.79. Appr ...

Shares of Sierra Wireless Rise Above Pre...

Sierra Wireless (NASDAQ:SWIR) traded at a new 52-week high today of $13.03. This new h ...

Seagate Technology: 52-Week High Recentl...

Shares of Seagate Technology (NASDAQ:STX) traded at a new 52-week high today of $45.50. ...

Reinsurance Group of America: The Winnin...

Reinsurance Group of America (NYSE:RGA) traded today at a new 52-week high of $69.15. ...

Targa Resources Partners: 52-Week High R...

Shares of Targa Resources Partners (NASDAQ:NGLS) traded at a new 52-week high today of ...

Recent 52-Week High Exceeded in Shares o...

Shares of Hospira (NYSE:HSP) traded today at $38.50, breaking its 52-week high. Approx ...

Shares of Heartland Payment Systems Rise...

Heartland Payment Systems (NYSE:HPY) traded today at a new 52-week high of $37.17. So ...

Most Popular Video News